Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

m-AMSA and PALA: Two new agents in cancer chemotherapy

Summary

4′-(9-Acridinylamino)methanesulfon-m-anisidide (m-AMSA) and N-(phosphonacetyl)-l-aspartate (PALA) are two new anticancer agents that have been recently introduced into clinical investigation. This review summarizes the preclinical information that has accumulated with these compounds as well as the very preliminary data presently available from early clinical trials. This information indicates the promising potential of m-AMSA and PALA in the treatment of cancer.

This is a preview of subscription content, log in to check access.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

References

  1. 1.

    Baguley, B. C., Falkenhaug, E. M., Rastrick, J. M., Marbrook, J.: An assessment of the immunosuppressive activity of the antitumour compound 4′-[9-acridinyl)amino]methanesulfon-m-anisidide (m-AMSA). Eur. J. Cancer 10, 169 (1974)

  2. 2.

    Byrd, D. M.: Antiviral activities of 4′-(9-acridinylamino)-methanesulfon-m-aniside (SN11841). Ann. NY Acad. Sci. 284, 463 (1977)

  3. 3.

    Cain, B. F., Atwell, G. J.: The experimental antitumour properties of three congeners of the acridylmethanesulphonailide (AMSA) series. Eur. J Cancer 10, 539 (1974)

  4. 4.

    Carter, S. K.: Clinical trials in cancer chemotherapy. Cancer 40, 544 (1977)

  5. 5.

    Carter, S. K.: The clinical evaluation of analogues: I. The overall problem. Cancer Chemother. Pharmacol. 1, 69 (1978)

  6. 6.

    Chadwick, M., Silveira, D. M., MacGregor, J. A., Branfman, A. R., Liss, R. H., Yesair, D. W.: Physiological disposition of PALA in several species. Proc. Am. Assoc. Cancer Res. 19, 182 (1978)

  7. 7.

    Collins, K. D., Stark, G. R.: Aspartate transcarbamylase. Interaction with the transition state analog N-(phosphonacetyl)-l-aspartate. J. Biol. Chem. 246, 6599 (1971)

  8. 8.

    Cooney, D. A., Karlowicz, M. G., Cubillan, J., Roettger, M., Jayaram, H. N.: An enzymatic technique for measuring N-phosphonacetyl-l-aspartic acid in tissues. Cancer Treat. Rep. 62, 1503 (1978)

  9. 9.

    Corbett, T. H., Griswold, D. P., Jr., Roberts, B. J., Peckham, J. C., Schabel, F. M., Jr.: Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 40, 2660 (1977)

  10. 10.

    Cysyk, R. L., Shoemaker, D., Adamson, R. H.: The pharmacologic disposition of 4′-(9-acridinylamino)methanesulfon-m-anisidide in mice and rats. Drug Metab. Dispos. 5, 579 (1977)

  11. 11.

    Cysyk, R. L., Shoemaker, D., Ayers, O. C., Adamson, R. H.: Oral absorption and selective tissue localization of 4′-(9-acridinylamino)-methanesulfon-m-anisidide. Pharmacology 16, 206 (1978)

  12. 12.

    Deaven, L. L., Oka, M. S., Tobey, R. A.: Cell-cycle-specific chromosome damage following treatment of cultured Chinese hamster cells with 4′[(9-acridinyl)-amino]methanesulfon-m-anisidide-HCl. J. Natl. Cancer Inst. 60, 1155 (1978)

  13. 13.

    DeVita, V. T., Jr., Schein, P. S.: The use of drugs in combination for the therapy of cancer. N. Engl. J. Med. 288, 988 (1973)

  14. 14.

    DeVita, V. T., Jr., Lewis, B. J., Rozencweig, M., Muggia, F. M.: The chemotherapy of Hodgkin's disease: Past experiences and future directions. Cancer 42, 979 (1978)

  15. 15.

    Furlong, N. B., Sato, J., Brown, T., Chavez, F., Hurlbert, R. B.: Induction of limited DNA damage by the antitumor agent Cain's acridine. Cancer Res. 38, 1329 (1978)

  16. 16.

    Goldin, A., Venditti, J. M., Muggia, F. M., Rozencweig, M., DeVita, V. T.: New animal models. In: Proceedings of the XII International Cancer Congress. Buenos Aires, Pergamon (in press, 1979)

  17. 17.

    Gormley, P. E., Sethi, V. S., Cysyk, R. L.: Interaction of 4′-(9-acridinylamino)methansulfon-m-anisidide with DNA and inhibition of oncornavirus reverse transcriptase and cellular nucleic acid polymerases. Cancer Res. 38, 1300 (1978)

  18. 18.

    Jacobs, E. M., Muggia, F. M., Rozencweig, M.: Chemotherapy of testicular cancer: From palliation to curative adjuvant therapy. Semin. Oncol. 6, 3 (1979)

  19. 19.

    Jayaram, H. N., Cooney, D. A., Vistica, D. T., Kariya, S., Johnson, R. K.: Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-l-aspartate. Cancer Treat. Rep. (in press, 1979)

  20. 20.

    Johnson, R. K.: Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-l-aspartate by uridine or carbamyl-dl-aspartate in vivo. Biochem. Pharmacol. 26, 81 (1977)

  21. 21.

    Johnson, R. K., Chitnis, M. P., Goldin, A.: Characteristics of resistance and cross-resistance in vivo of a subline of P388 leukemia resistant to adriamycin. Pharmacologist 18, 173 (1976)

  22. 22.

    Johnson, R. K., Swyryd, E. A., Stark, G. R.: Effects of N-(phosphanacetyl)-l-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of asparate transcarbamylase. Cancer Res 38, 371 (1978)

  23. 23.

    Kempe, T. D., Swyryd, E. A., Bruist, M., Stark, G. R.: Stable mutants of mamalian cells that overproduce the first three enzymes of pyrimidine nucleotide biosynthesis. Cell 9, 541 (1976)

  24. 24.

    Legha, S. S., Gutterman, J. U., Hall, S. W., Benjamin, R. S., Burgess, M. A., Valdivieso, M., Bodey, G. P.: Phase I clinical investigation of 4′-(9-acridinylamino)methanesulfon-m-anisidide (NSC-249992), a new acridine derivative. Cancer Res. 38, 3712 (1978)

  25. 25.

    Mellanby, E.: Report on work carried out in the pharmacological laboratory, Sheffield University. British Empire Cancer Campaign 10th Annual Report, p. 102, 1933

  26. 26.

    Muggia, F. M., Rozencweig, M., Von Hoff, D. D.: Evaluation of anticancer drugs: Analysis of recent results by disease. In: Recent Advances in Cancer Treatment. Tagnon, H. J., Staquet, M. J. (eds.), p. 187. New York: Raven Press 1977

  27. 27.

    Muggia, F. M., McGuire, W. P., Rozencweig, M.: Rationale, design and methodology of Phase II clinical trials. In: Methods in Cancer Research. Bush, H., DeVita, V. T., Jr. (eds.) 17, 199 (1979)

  28. 28.

    Muggia, F. M., Rozencweig, M., Bono, V. H., Jacobs, E. M., Jr.: Platinum: The trail from an inert electrode to a therapeutic solution. Cancer Treat. Rep. (in press, 1979)

  29. 29.

    Nayak, R., Martin, D., Stolfi, R., Furth, J., Spiegelman, S.: Pyrimidine nucleosides enhance the anti-cancer activity of FU and augment its incorporation into nuclear RNA. Proc. Am. Assoc. Cancer Res. 19, 63 (1978)

  30. 30.

    Osieka, R., Houchens, D. P., Goldin, A., Johnson, R. K.: Chemotherapy of human colon cancer xenografts in athymic nude mice. Cancer 40, 2640 (1977)

  31. 31.

    Rozencweig, M., Von Hoff, D. D., Venditti, J. M., Muggia, F. M.: Correlation between experimental activity of anticancer agents and their hematologic toxicity in man. Blood 48, 984 (1976)

  32. 32.

    Rozencweig, M., Von Hoff, D. D., Henney, J. E., Muggia, F. M.: VM 26 and VP 16-213: A comparative analysis. Cancer 40, 334 (1977)

  33. 33.

    Rozencweig, M., Von Hoff, D. D., Slavik, M., Muggia, F. M.: cis-Diamminedichloroplatinum (II): A new anticancer drug. Ann. Intern. Med. 86, 803 (1977)

  34. 34.

    Rozencweig, M., De Sloover, C., Von Hoff, D. D., Tagnon, H. J., Muggia, F. M.: Anthracycline derivatives in new drug development programs. Cancer Treat. Rep. (in press, 1979)

  35. 35.

    Schabel, F. M., Jr., Laster, W. R., Jr., Rose, W. C.: The role of experimental tumor systems. In: Lung Cancer: Progress in Therapeutic Research. Muggia, F. M., Rozencweig, M. (eds.), p. 15. New York: Raven Press 1979

  36. 36.

    Shoemaker, D. D., Legha, S. S., Cysyk, R. L.: Selective localization of 4′(9-acridinylamino)methanesulfon-m-anisidide in B16 melanoma. Pharmacology 16, 221 (1978)

  37. 37.

    Strong, J. M., Kinney, Y. E., Branfman, A. R., Cysyk, R. L.: Determination of N-(phosphonacetyl)-l-aspartic acid (PALA) in biological fluids by gas chromatography and by selected ion monitoring. Cancer Treat. Rep. (in press, 1979)

  38. 38.

    Sweeney, M. J., Hoffman, D. H., Poore, G. A.: Enzymes in pyrimidine biosynthesis. Adv. Enzyme Regul. 9, 51 (1970)

  39. 39.

    Tobey, R. A., Deaven, L. L., Oka, M. S.: Kinetic response of cultured Chinese hamster cells to treatment with 4′-[(9-acridinyl)-amino]methanesulfon-m-anisidide-HCl. J. Natl. Cancer Inst. 60, 1147 (1978)

  40. 40.

    Von Hoff, D. D., Rozencweig, M., Soper, W. T., Helman, L. J., Penta, J. S., Davis, H. L., Muggia, F. M.: Whatever happened to NSC? — An analysis of clinical results of discontinued anticancer agents. Cancer Treat. Rep. 61, 759 (1977)

  41. 41.

    Von Hoff, D. D., Howser, D., Gormley, P., Bender, R. A., Glaubiger, D., Levine, A. S., Young, R. C.: Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule. Cancer Treat. Rep. 62, 1421 (1978)

  42. 42.

    Waring, M. J.: DNA-binding characteristics of acridinylmethanesulphonanilide drugs: Comparison with antitumour properties. Eur. J. Cancer 12, 995 (1976)

  43. 43.

    Wilson, W. R.: Studies on mechanism of action of an experimental antitumor drug. Chem. N.Z. 37, 148 (1973)

  44. 44.

    Yoshida, T., Stark, G. R., Hoogenraad, N. J.: Inhibition by N-(Phosphonacetyl)-l-aspartate of aspartate transcarbamylase activity and drug-induced cell proliferation in mice. J. Biol. Chem. 249, 6951 (1974)

  45. 45.

    Young, J. E., Prager, M. D., Atkins, I. C.: Comparative activities of aspartate transcarbamylase in various tissues of the rat (32224). Proc. Soc. Exp. Biol. Med. 125, 860 (1967)

Download references

Author information

Correspondence to M. Rozencweig.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Rozencweig, M., Von Hoff, D.D., Cysyk, R.L. et al. m-AMSA and PALA: Two new agents in cancer chemotherapy. Cancer Chemother. Pharmacol. 3, 135–141 (1979). https://doi.org/10.1007/BF00262414

Download citation

Keywords

  • Clinical Trial
  • Cancer Research
  • Preliminary Data
  • Anticancer Agent
  • Clinical Investigation